Comprehensive cancer center
Appears in 1 story
Led the ImmunoPRISM trial
Doctors at Dana-Farber Cancer Institute gave teclistamab, a bispecific antibody already approved for advanced myeloma, to 45 patients with high-risk smoldering multiple myeloma. Complete remission followed in 77.8% of them.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
